Clinical pharmacodynamics of obeldesivir versus remdesivir
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00969-24 ↗Kurz gefasst
Leserbrief in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Isa Faghihi und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Alanine, Adenosine Monophosphate, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Texas Southwestern Medical Center, Dallas, Texas, USA.
ORCID-Profile: Isa Faghihi, Victoria C Yan
Zitieren
APA
Faghihi, I., & Yan, V. C. (2024). Clinical pharmacodynamics of obeldesivir versus remdesivir. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00969-24
Vancouver
Faghihi I, Yan VC. Clinical pharmacodynamics of obeldesivir versus remdesivir. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00969-24
BibTeX
@article{Faghihi2024,
author = {Faghihi, Isa and Yan, Victoria C},
title = {Clinical pharmacodynamics of obeldesivir versus remdesivir},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00969-24}
}
EUVIMED